The cost-effectiveness and relapse-reduction benefit of introducing adjuvant nivolumab for patients with completely with resected melanoma with lymph node involvement or metastatic disease in the UK
Authors:
Ntais D, Batteson R, Hart R, Hemstock M and Lee D.
Publication type:
Conference Proceedings – Poster
Publication Name:
ISPOR Europe 2019
Citation:
Ntais D, Batteson R, Hart R, Hemstock M and Lee D. The cost-effectiveness and relapse-reduction benefit of introducing adjuvant nivolumab for patients with completely with resected melanoma with lymph node involvement or metastatic disease in the UK. ISPOR Europe 2019. Copenhagen, Denmark. 2-6 November 2019. Poster PCN226.
